182 related articles for article (PubMed ID: 38726789)
21. Impact and Therapeutic Potential of PPARs in Alzheimer's Disease.
Heneka MT; Reyes-Irisarri E; Hüll M; Kummer MP
Curr Neuropharmacol; 2011 Dec; 9(4):643-50. PubMed ID: 22654722
[TBL] [Abstract][Full Text] [Related]
22. Activation of Liver X Receptors and Peroxisome Proliferator-Activated Receptors by Lipid Extracts of Brown Seaweeds: A Potential Application in Alzheimer's Disease?
Martens N; Zhan N; Voortman G; Leijten FPJ; van Rheenen C; van Leerdam S; Geng X; Huybrechts M; Liu H; Jonker JW; Kuipers F; Lütjohann D; Vanmierlo T; Mulder MT
Nutrients; 2023 Jun; 15(13):. PubMed ID: 37447330
[TBL] [Abstract][Full Text] [Related]
23. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
24. Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators.
Jayaraj RL; Azimullah S; Beiram R
Saudi J Biol Sci; 2020 Feb; 27(2):736-750. PubMed ID: 32210695
[TBL] [Abstract][Full Text] [Related]
25. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.
Latruffe N; Vamecq J
Biochimie; 1997; 79(2-3):81-94. PubMed ID: 9209701
[TBL] [Abstract][Full Text] [Related]
26. A tau fragment links depressive-like behaviors and cognitive declines in Alzheimer's disease mouse models through attenuating mitochondrial function.
Wang Y; Wang J; Chen H; Li X; Xu R; Gao F; Yu H; Li F; Qin D; Wang J; Shi Y; Li Y; Liu S; Zhang X; Ding S; Hu Y; Huang L; Gao XY; Lu Z; Luo J; Wang ZH
Front Aging Neurosci; 2023; 15():1293164. PubMed ID: 38131009
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
28. Role of Phytoconstituents as PPAR Agonists: Implications for Neurodegenerative Disorders.
Sanjay ; Sharma A; Lee HJ
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944727
[TBL] [Abstract][Full Text] [Related]
29. Fenofibrate reduces amyloidogenic processing of APP in APP/PS1 transgenic mice via PPAR-α/PI3-K pathway.
Zhang H; Gao Y; Qiao PF; Zhao FL; Yan Y
Int J Dev Neurosci; 2014 Nov; 38():223-31. PubMed ID: 25447788
[TBL] [Abstract][Full Text] [Related]
30. Effect of rosiglitazone on amyloid precursor protein processing and Aβ clearance in streptozotocin-induced rat model of Alzheimer's disease.
Wang L; Liu W; Fan Y; Liu T; Yu C
Iran J Basic Med Sci; 2017 May; 20(5):474-480. PubMed ID: 28656081
[TBL] [Abstract][Full Text] [Related]
31. PPAR agonists for the treatment of neuroinflammatory diseases.
Titus C; Hoque MT; Bendayan R
Trends Pharmacol Sci; 2024 Jan; 45(1):9-23. PubMed ID: 38065777
[TBL] [Abstract][Full Text] [Related]
32. Alzheimer's disease: relevant molecular and physiopathological events affecting amyloid-β brain balance and the putative role of PPARs.
Zolezzi JM; Bastías-Candia S; Santos MJ; Inestrosa NC
Front Aging Neurosci; 2014; 6():176. PubMed ID: 25120477
[TBL] [Abstract][Full Text] [Related]
33. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease.
Goozee KG; Shah TM; Sohrabi HR; Rainey-Smith SR; Brown B; Verdile G; Martins RN
Br J Nutr; 2016 Feb; 115(3):449-65. PubMed ID: 26652155
[TBL] [Abstract][Full Text] [Related]
34. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
35. The Role of PPARs in Disease.
Wagner N; Wagner KD
Cells; 2020 Oct; 9(11):. PubMed ID: 33126411
[TBL] [Abstract][Full Text] [Related]
36. Oxidative Damage and Antioxidant Response in Frontal Cortex of Demented and Nondemented Individuals with Alzheimer's Neuropathology.
Fracassi A; Marcatti M; Zolochevska O; Tabor N; Woltjer R; Moreno S; Taglialatela G
J Neurosci; 2021 Jan; 41(3):538-554. PubMed ID: 33239403
[TBL] [Abstract][Full Text] [Related]
37. Recent Insights on the Role of PPAR-β/δ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy.
Strosznajder AK; Wójtowicz S; Jeżyna MJ; Sun GY; Strosznajder JB
Neuromolecular Med; 2021 Mar; 23(1):86-98. PubMed ID: 33210212
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?
Gupta M; Mahajan VK; Mehta KS; Chauhan PS; Rawat R
Arch Dermatol Res; 2015 Nov; 307(9):767-80. PubMed ID: 25986745
[TBL] [Abstract][Full Text] [Related]
39. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
40. Garcinoic acid prevents β-amyloid (Aβ) deposition in the mouse brain.
Marinelli R; Torquato P; Bartolini D; Mas-Bargues C; Bellezza G; Gioiello A; Borras C; De Luca A; Fallarino F; Sebastiani B; Mani S; Sidoni A; Viña J; Leri M; Bucciantini M; Nardiello P; Casamenti F; Galli F
J Biol Chem; 2020 Aug; 295(33):11866-11876. PubMed ID: 32616652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
